N-Trifluoroacetyladriamycin
| Code | Size | Price |
|---|
| TAR-T25892-5mg | 5mg | £491.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
N-Trifluoroacetyladriamycin is a metabolite of Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar). Valrubicin is a chemotherapy drug utilized to treat bladder cancer. Valrubicin is the anthracycline doxorubicin analog and is administered by infusion directly into the bladder.
CAS:
26295-56-7
Formula:
C29H28F3NO12
Molecular Weight:
639.533
Purity:
0.98
SMILES:
COc1cccc2C(=O)c3c(O)c4C[C@](O)(CC(O[C@H]5C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
References
1. Krishan A, Dutt K, Israel M, Ganapathi R. Comparative effects of adriamycin and N-trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro. Cancer Res. 1981 Jul;41(7):2745-50. PubMed PMID: 6972801.
2. Chuang RY, Chuang LF, Kawahata RT, Israel M. Effect of N-trifluoroacetyladriamycin-14-valerate on [3H]thymidine uptake and DNA synthesis of human lymphoma cells. J Biol Chem. 1983 Jan 25;258(2):1062-5. PubMed PMID: 6822492.
3. Israel M, Modest EJ, Frei E 3rd. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 1975 May;35(5):1365-8. PubMed PMID: 1054622.
4. Sweatman TW, Parker RF, Israel M. Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study. Cancer Chemother Pharmacol. 1991;28(1):1-6. PubMed PMID: 2040028.